Heinz Gisslinger
Overview
Explore the profile of Heinz Gisslinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
7558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda J, Bose P, Dohner K, et al.
Blood
. 2024 Aug;
144(17):1813-1820.
PMID: 39116296
With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons....
2.
Rusing L, Kozakowski N, Jeryczynski G, Vospernik L, Riedl J, Reiter T, et al.
Hematology
. 2024 Feb;
29(1):2311600.
PMID: 38329272
Objective: Cast nephropathy (CN) is the leading cause of acute kidney injury (AKI) in multiple myeloma (MM). Since it is sparsely documented why some patients with CN do achieve a...
3.
Gisslinger H
Turk J Haematol
. 2023 Dec;
40(4):266-268.
PMID: 38050364
Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life,...
4.
Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, et al.
Eur J Haematol
. 2023 Oct;
112(3):379-391.
PMID: 37899734
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance and resistance to HU. Methods: This phase...
5.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al.
Leukemia
. 2023 Aug;
37(10):2129-2132.
PMID: 37634011
No abstract available.
6.
Carobbio A, Vannucchi A, Rumi E, De Stefano V, Rambaldi A, Carli G, et al.
Blood Cancer J
. 2023 Jul;
13(1):115.
PMID: 37507408
No abstract available.
7.
Ivanov D, Milosevic Feenstra J, Sadovnik I, Herrmann H, Peter B, Willmann M, et al.
Am J Hematol
. 2023 Feb;
98(5):770-783.
PMID: 36814396
Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute...
8.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, et al.
Blood
. 2022 Nov;
141(8):917-929.
PMID: 36356299
Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs)....
9.
Guglielmelli P, Kiladjian J, Vannucchi A, Duan M, Meng H, Pan L, et al.
Ther Adv Hematol
. 2022 Sep;
13:20406207221118429.
PMID: 36105914
Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF...
10.
Marchetti M, Vannucchi A, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al.
Lancet Haematol
. 2022 Mar;
9(4):e301-e311.
PMID: 35358444
Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution. The results of several randomised trials for...